Search Results
Your search for ,WhO matches 21072 pages
Showing 351 - 400More Patients With Cancer Are Using Crowdfunding to Pay for Care—and Coming up Short
Studies show that cancer is one of the leading diseases among all medical crowdfunding campaigns, with GoFundMe being the most popular platform for peer-to-peer medical donations. A new study by researchers at the American Cancer Society (ACS) has found that a growing number of cancer survivors are ...
FDA Approves New Interchangeable Biosimilar to Pertuzumab
The U.S. Food and Drug Administration (FDA) has approved pertuzumab-dpzb (Poherdy) as an interchangeable biosimilar to pertuzumab (Perjeta). This is the first approval of a biosimilar for pertuzumab. Pertuzumab-dpzb is a HER2/neu receptor antagonist indicated for the following: Use in combination...
FDA Approves Ziftomenib for NPM1-Positive AML
On November 13, 2025, the U.S. Food and Drug Administration (FDA) approved ziftomenib (Komzifti), a menin inhibitor, for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options...
Transfusion Access Central to Hospice Decision-Making Among Patients With Blood Cancers
Based on the results of a multicenter cross-sectional survey study published in JAMA Network Open by Raman et al, patients with blood cancer who were potentially hospice-eligible placed the greatest importance on transfusion access compared with routine hospice services. “The high value placed on...
Advanced Epithelial Ovarian Cancer: First-Line PARP Inhibitor Maintenance Therapy and Survival
A systematic review and meta-analysis published in JAMA Network Open found first-line PARP inhibitor maintenance after platinum-based chemotherapy was linked to improved progression-free survival across multiple patient populations with advanced-stage epithelial ovarian cancer. However, according...
Exercise Training Improves Strength and Quality of Life for Patients With Metastatic Breast Cancer
Supervised aerobic and resistance exercise can improve the physical performance and strength of patients living with metastatic breast cancer, according to new data from the PREFERABLE-EFFECT study that was presented by Anne May, PhD, during the Advanced Breast Cancer Eighth International Consensus ...
Supportive Care: Most Clinic Staff Prefer People-Focused vs Digital Solutions
Most cancer clinic staff prefer a team-based approach to supportive cancer care services over a technology-based approach, according to the results of a mixed-methods study of supportive care perceptions that was published in JNCCN—Journal of the National Comprehensive Cancer Network. The study...
Longtime FDA Innovator Appointed as Director of CDER
The U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) announced that Richard Pazdur, MD, has been appointed Director of the Center for Drug Evaluation and Research (CDER). Dr. Pazdur is a 26-year veteran of the FDA and the Founding Director of its...
Survey Highlights Unmet Needs Among Young Women With Advanced Breast Cancer
Almost half of all women (48%) under the age of 40 who are living with advanced breast cancer have children under the age of 18, and 64% of these young patients also experience employment disruptions after they are diagnosed, according to findings from a survey conducted by the Young Survival...
Study Finds Gaps Exist in Quality of Cancer Care for Incarcerated People
In the United States, the incarcerated population is aging. About 15% of incarcerated adults, or approximately 175,000 people, are now 55 years or older. As the incarcerated population ages, cancer has become one of the greatest threats to their health. And despite the growing prevalence, cancer...
Armando E. Giuliano, MD, To Be Honored With 2025 William L. McGuire Memorial Lecture Award at SABCS
Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering work on sentinel lymph node biopsy for patients with breast cancer, which has transformed the...
ASCO and ONS Issue First Collaborative Guideline on Extravasation
ASCO and the Oncology Nursing Society (ONS) have released their first joint guideline on managing extravasation, an uncommon but potentially life-threatening complication of intravenous antineoplastic therapy.1 Extravasation occurs when an agent with tissue-damaging properties leaks from the...
Making Clinical Trials More Accessible: New Report Highlights Barriers and Solutions
Clinical trials remain out of reach for many Americans, with only 7% of patients with cancer participating in clinical trials, according to a new report from the American Society of Clinical Oncology’s (ASCO) State of Cancer Care in America series. Experts agree that access to trials is a key...
The Consequences of Climate Change on Cancer Development and Patient Care
In 2021, The ASCO Post had a wide-ranging discussion with Robert A. Hiatt, MD, PhD, Professor in the Department of Epidemiology and Biostatistics at the University of California, San Francisco (UCSF), and Associate Director of Population Sciences at UCSF Helen Diller Family Comprehensive Cancer...
Reducing the Impact of Climate-Induced Events on Patients and Oncology Staff
Although 2023 made headlines as the hottest year in human history,1 drawing the world closer to breaching the goals outlined in the Paris Agreement to substantially reduce global greenhouse gas emissions to limit global warming to well below 2°C above preindustrial levels (and preferably to...
Multidrug-Resistant Ulcerative Colitis: Response to CD19 CAR T-Cell Therapy in a Single Case
In a letter to the editor published in The New England Journal of Medicine, Markus F. Neurath, MD, of Friedrich-Alexander-University Erlangen–Nuremberg, Erlangen, Germany, and colleagues described the course of treatment in a 21-year-old woman with severe multidrug-resistant ulcerative colitis who...
Immunotherapy Combination Active in Patients With Large B-Cell Lymphoma Who Are Not Eligible for Autologous Stem Cell Transplant
In the global phase III SUNMO trial, the combination of a bispecific antibody and an antibody-drug conjugate was compared with rituximab plus gemcitabine and oxaliplatin (GemOx) in the treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL) who were ineligible for autologous...
Safety and Benefit of Radiation Therapy for High-Risk Muscle-Invasive Bladder Cancer
Following cystectomy, patients with muscle-invasive bladder cancer at high risk for recurrence may safely be treated with radiotherapy and may achieve an improvement in locoregional control compared with observation. These findings, which come from the phase III BART trial presented in a plenary...
Intensity-Modulated Radiation Therapy vs Proton Therapy for Oropharyngeal Cancer
The phase III TORPEdO trial reported no meaningful differences between intensity-modulated radiation therapy (IMRT) and proton beam therapy at 1 year in terms of patient-reported quality of life, swallowing function, or feeding tube dependence for individuals with locally advanced oropharyngeal...
Impact of Concomitant Noncancer Medications on Outcomes in Breast Cancer
An evaluation of noncancer medications used concomitantly with cancer therapies for patients with breast cancer showed that proton pump inhibitors specifically were associated with worse survival outcomes and with an increased risk of grade 3 or higher adverse events than other classes of therapy....
Adding an Investigational Monoclonal Antibody to Ibrutinib May Allow Patients With CLL to Discontinue Daily Treatment
Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the Western hemisphere, accounting for between 25% and 35% of all leukemias in the United States. According to the American Cancer Society, nearly 24,000 new cases of CLL will be diagnosed in the United States this year,...
A Serendipitous Fall May Have Saved My Life
In the spring of 2024, I was preparing to compete in a Half Ironman triathlon and was not surprised when I began experiencing tightness in my groin. I just figured it was the byproduct of specific endurance training I was doing in each discipline, including running, biking, and swimming, to get...
Physician-Complementing Artificial Intelligence in Oncology
Use of artificial intelligence (AI) in oncology is advancing rapidly. AI was first used for reading radiology images and analyzing pathology slides. More recently, use of AI has expanded to analyzing large clinical data sets (big data). The next envisioned role for AI in oncology encompasses many ...
Hepatic Arterial Infusion Pump Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma
In a Dutch phase II trial (PUMP-2) reported in the Journal of Clinical Oncology, Franssen et al found that use of hepatic arterial infusion pump (HAIP) chemotherapy with floxuridine, with or without concomitant gemcitabine, plus cisplatin showed good activity and improved overall survival in...
Basser Center for BRCA Announces Two Award Winners
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, is honoring Alan D. D'Andrea, MD, of Dana-Farber Cancer Institute, with the 2025 BRCA...
Extended ERSPC Analysis Demonstrates Long-Term Mortality Benefit of PSA Screening for Prostate Cancer
In an updated analysis published in The New England Journal of Medicine, Roobol et al reported long-term findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) on the survival benefit of prostate-specific antigen (PSA) screening. The study, which was initiated in 1993, ...
Extensive LA-Area Fires Altered Blood Proteins in Firefighters
Researchers have found that firefighters who battled the massive urban fires in the Los Angeles area in January 2025 developed physiologic changes that may increase their risk of diseases, including cancer. The research, which was published by Furlong et al in the Journal of Occupational and...
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistically significant and clinically meaningful improvement in overall survival, with benefit seen...
New Report: Lung Cancer Advancements Are Saving More Lives Than Ever, but Funding Cuts May Hinder Progress
The American Lung Association has released its 2025 “State of Lung Cancer” report, which reveals great strides in efforts to end lung cancer—the leading cause of cancer-related deaths in the United States. This year, nearly 227,000 people in the United States will be diagnosed with lung cancer....
Study Finds Breast Cancer Risk Varies Between Different Hormonal Contraceptives
Some common hormonal contraceptives are linked to a slightly higher risk of breast cancer than others. This is shown by a new study from Uppsala University, in which researchers followed more than 2 million women and teenage girls in Sweden to identify how different hormonal contraceptives affect...
Diminishing the National Cancer Institute Threatens Americans
In an effort to reduce the size of government, the current administration has proposed an across the board 37% reduction1 in funding for the National Cancer Institute (NCI). This will result in approval of only 4% of applications2 from scientists at universities and cancer centers, with 96% of all ...
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients with platinum-resistant recurrent ovarian cancer, in the randomized, double-blind, phase III...
Deep Learning and Mammography for Identifying Interval Breast Cancers
A deep learning algorithm developed for processing digital screening mammograms, Mirai, was able to detect interval breast cancers and identify women who would benefit from more frequent screenings, according to the results of a UK retrospective study published in Radiology. “If we called back 20% ...
My 50 Years in Lymphoma: Lessons Learned?
In the 50 years now since my fellowship training, there have been major advances in the diagnosis, staging, prognostic scoring, treatment, and response assessment of lymphomas. To conjure up the future, we must first appreciate the present by understanding how it arose from the past.1 So, a trip in ...
Investigational Antibody-Drug Conjugate in Previously Treated SCLC
About 13% of all lung cancers in the United States are small cell lung cancer (SCLC), and approximately 87% are non–small cell lung cancer (NSCLC). Together, these lung cancers are the second most common cancer diagnosed in both men and women, excluding skin cancer. Usually a very aggressive...
Global Analysis Uncovers Wide Inequalities in Care for Breast, Cervical, and Ovarian Cancers
A major study of three of the most common cancers in women, conducted by the Cancer Survival Group at the London School of Hygiene & Tropical Medicine, found variations in the stage of disease at diagnosis, the type of treatment, and the extent to which treatment was consistent with...
Testing for Melanoma Sentinel Lymph Node Status
A gene expression profile–based test coupled with clinicopathologic factor assessment was able to consistently identify patients with melanoma who were at a low risk for their disease spreading to the sentinel lymph nodes, according to findings from the MERLIN_001 trial published in JAMA Surgery....
Cognitive Function and Statin Administration During Doxorubicin-Based Cancer Treatment
Contrary to previous research, a preplanned secondary analysis of the multicenter PREVENT trial, reported by W.Gregory Hundley, MD, FACC, of Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, and colleagues in ...
Physician-Complementing Artificial Intelligence in Oncology
Use of artificial intelligence (AI) in oncology is advancing rapidly. AI was first used for reading radiology images and analyzing pathology slides. More recently, use of AI has expanded to analyzing large clinical data sets (big data). The next envisioned role for AI in oncology encompasses many ...
Elironrasib Active in KRAS G12C–Resistant NSCLC
Elironrasib, a novel RAS G12C–selective tri-complex inhibitor, demonstrated initial clinical activity and a differentiated safety profile in heavily pretreated patients with non–small cell lung cancer (NSCLC) and KRAS G12C mutations, according to findings from a phase I trial presented at the 2025...
Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma
In an individual-patient pooled analysis reported in the Journal of Clinical Oncology, Raimondi et al found that neoadjuvant treatment with dual CTLA-4/PD-(L)1 immune checkpoint inhibitors (ICIs) was associated with higher pathologic response rates vs perioperative FLOT (fluorouracil, leucovorin,...
ASTRO Announces 2025 Awards and Research Grants
The American Society for Radiation Oncology (ASTRO) recognized the recipients of the 2025 Gold Medal awards and other high-profile honors during its recent Annual Meeting. ASTRO also recognized the recipients of its 2025 research grants and fellowships, including awards cosponsored by patient,...
Disitamab Vedotin Plus Toripalimab vs Chemotherapy in HER2-Expressing Advanced Urothelial Cancer
In a Chinese phase III trial (RC48-C016) reported at the recent ESMO Congress and in The New England Journal of Medicine, Sheng et al found that the combination of the HER2-directed antibody-drug conjugate disitamab vedotin and the PD-1 inhibitor toripalimab-tpzi improved progression-free survival...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved outcomes vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy. Results...
Revumenib Approved by FDA for NPM1-Positive AML
On October 24, 2025, the U.S. Food and Drug Administration (FDA) approved revumenib (Revuforj), a menin inhibitor, for the treatment of relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation, in adult and pediatric patients 1 year and older who have no...
FDA Approves Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma
On October 23, 2025, the U.S. Food and Drug Administration (FDA) approved belantamab mafodotin-blmf (Blenrep), a B-cell maturation antigen (BCMA)–directed antibody and microtubule inhibitor conjugate, in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or...
President Biden Completes Radiation Therapy Course
President Joe Biden has completed his course of radiation therapy for prostate cancer, which he recently marked by ringing the ceremonial bell alongside his radiation oncology care team. According to a report from People, President Biden’s daughter Ashley Biden shared the moment on her Instagram...
PD-L1 Plus CTLA-4 Inhibition for Renal Cell Carcinoma Following Resection: RAMPART
Combination immunotherapy significantly improved disease-free survival after surgery in patients with primary renal cell carcinoma (RCC), according to results from the phase III RAMPART trial. These findings were presented at the European Society for Medical Oncology (ESMO) Congress 2025 by James...
How the Proliferation of Fraudulent Scientific Papers Is Threatening the Integrity of Cancer Research
There is a perception among many scientists that scientific fraud is a rare occurrence, resulting from the actions of a few isolated bad actors. However, an extensive investigation by Reese A.K. Richardson, PhD, postdoctoral fellow at the Center for Science of Science and Innovation, Kellogg School ...
